R E Hershberger

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Clinical outcomes, quality of life, and cost outcomes after cardiac transplantation
    R E Hershberger
    Division of Medicine Cardiology, Heart Failure and Transplant Cardiology, Oregon Health Sciences University, Portland 97201, USA
    Am J Med Sci 314:129-38. 1997
  2. ncbi Daclizumab to prevent rejection after cardiac transplantation
    Ray E Hershberger
    Department of Medicine Cardiology, UHN 62, Oregon Health and Science University, Portland, OR 97239, USA
    N Engl J Med 352:2705-13. 2005
  3. ncbi Distribution and declines in cardiac allograft radionuclide left ventricular ejection fractions in relation to late mortality
    R E Hershberger
    The Oregon Cardiac Transplant Program, Oregon Health Sciences University, Portland, Oregon 97201 3098, USA
    J Heart Lung Transplant 20:417-24. 2001
  4. ncbi Familial dilated cardiomyopathy: echocardiographic diagnostic criteria for classification of family members as affected
    R E Hershberger
    Heart Failure Treatment Program, Department of Medicine, Oregon Health Sciences University, Portland 97201, USA
    J Card Fail 5:203-12. 1999
  5. ncbi A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation
    Ray E Hershberger
    Department of Medicine, Oregon Health and Science University, Portland, Ore 97201, USA
    Am Heart J 144:1081-6. 2002
  6. ncbi Prospective evaluation of an outpatient heart failure management program
    R E Hershberger
    Oregon Heart Failure Project, Heart Failure Treatment Program, Oregon Health Sciences University, Portland, Oregon 97201-3098, USA
    J Card Fail 7:64-74. 2001
  7. ncbi Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease
    P M Jakobs
    Department of Medicine, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
    J Card Fail 7:249-56. 2001
  8. ncbi Factors influencing knowledge of and adherence to self-care among patients with heart failure
    H Ni
    Department of Public Health, Oregon Health Sciences University, Portland 97201 3098, USA
    Arch Intern Med 159:1613-9. 1999
  9. ncbi Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy
    Sharie B Parks
    Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR, USA
    Am Heart J 156:161-9. 2008
  10. ncbi Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes
    M Silberbach
    Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon 97201, USA
    J Biol Chem 274:24858-64. 1999

Collaborators

  • H Ni
  • M Litt
  • Howard J Eisen
  • M Silberbach
  • Deirdre J Nauman
  • M S Slater
  • Robert Kormos
  • P J Hauptman
  • Robert Arnold
  • Brad Stuart
  • J A Spertus
  • Randall C Starling
  • Duanxiang Li
  • Jessica D Kushner
  • Donna Burgess
  • Sharie B Parks
  • Jason Cowan
  • Ana Morales
  • Susan Ludwigsen
  • Michael Jerosch-Herold
  • Emily L Hanson
  • Christopher B Komanapalli
  • Emily L Burkett
  • Sarah J Goodlin
  • Petra M Jakobs
  • Warren Toy
  • Mark R Vossler
  • Kelly Coates
  • Kathy A Crispell
  • P M Jakobs
  • Jorge Gonzalez-Quintana
  • David C Sheridan
  • Jimena Dagua
  • Peter S Rahko
  • Charles B Porter
  • Petra Jakobs
  • Amanda Peterson
  • Rami Alharethi
  • Diana Dutton
  • Howard K Song
  • Lars Hegnell
  • Melodie Burdette
  • Glenn Brady
  • Charles N Allen
  • Julie Partain
  • Emily Burkett
  • Randal R Nixon
  • Pasala S Ravichandran
  • Robert P Irwin
  • Uttam Tripathy
  • George Pantely
  • Valerie Sera
  • Christy Whitney
  • Ruth Medak
  • Dale G Renlund
  • Frederick Masoudi
  • Kathy Crispell
  • James F Cleary
  • Joan Teno
  • Thomas Rector
  • Jean Kutner
  • Kathleen Grady
  • Kathleen Dracup
  • Nicholas H Dienel
  • Hugh Keegan
  • Sylvia Bousman
  • K A Crispell
  • W Toy
  • T B Icenogle
  • K Schilling
  • E L Hanson
  • H Keegan

Detail Information

Publications26

  1. ncbi Clinical outcomes, quality of life, and cost outcomes after cardiac transplantation
    R E Hershberger
    Division of Medicine Cardiology, Heart Failure and Transplant Cardiology, Oregon Health Sciences University, Portland 97201, USA
    Am J Med Sci 314:129-38. 1997
    ..This shift ultimately is related to the reduced supply of donors relative to the demand. The ultimate impact of managed care on cardiac transplantation is not clear, but it probably will continue to reduce expenditures in the near term...
  2. ncbi Daclizumab to prevent rejection after cardiac transplantation
    Ray E Hershberger
    Department of Medicine Cardiology, UHN 62, Oregon Health and Science University, Portland, OR 97239, USA
    N Engl J Med 352:2705-13. 2005
    ..We conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transplant patients...
  3. ncbi Distribution and declines in cardiac allograft radionuclide left ventricular ejection fractions in relation to late mortality
    R E Hershberger
    The Oregon Cardiac Transplant Program, Oregon Health Sciences University, Portland, Oregon 97201 3098, USA
    J Heart Lung Transplant 20:417-24. 2001
    ..Despite widespread use of LVEF after transplantation, its normal range and prognostic value in cardiac allografts has not been defined...
  4. ncbi Familial dilated cardiomyopathy: echocardiographic diagnostic criteria for classification of family members as affected
    R E Hershberger
    Heart Failure Treatment Program, Department of Medicine, Oregon Health Sciences University, Portland 97201, USA
    J Card Fail 5:203-12. 1999
    ..The objective of this study is to evaluate an alternative diagnostic criteria for FDC based only on LVE with no measure of fractional shortening (FS)...
  5. ncbi A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation
    Ray E Hershberger
    Department of Medicine, Oregon Health and Science University, Portland, Ore 97201, USA
    Am Heart J 144:1081-6. 2002
    ..Each family reported to date has a unique mutation and variable degrees of cardiac conduction system, dilated cardiomyopathy, or skeletal muscle disease...
  6. ncbi Prospective evaluation of an outpatient heart failure management program
    R E Hershberger
    Oregon Heart Failure Project, Heart Failure Treatment Program, Oregon Health Sciences University, Portland, Oregon 97201-3098, USA
    J Card Fail 7:64-74. 2001
    ..The patients' QOL was improved over time with a change score of 11.2 (P <.001) at 3 months and 10.7 (P <.001) at 6 months. CONCLUSION: Our study shows the effectiveness of this heart failure outpatient management program...
  7. ncbi Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease
    P M Jakobs
    Department of Medicine, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
    J Card Fail 7:249-56. 2001
    ..Skeletal muscle disease was not observed in either family. CONCLUSIONS: Novel rod segment mutations in lamin A/C cause variable conduction system disease and dilated cardiomyopathy without skeletal myopathy...
  8. ncbi Factors influencing knowledge of and adherence to self-care among patients with heart failure
    H Ni
    Department of Public Health, Oregon Health Sciences University, Portland 97201 3098, USA
    Arch Intern Med 159:1613-9. 1999
    ..Patient education has been shown to be a key component in comprehensive heart failure management. Few data, however, are available regarding patients' knowledge of and adherence to self-care recommendations for the disease...
  9. ncbi Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy
    Sharie B Parks
    Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR, USA
    Am Heart J 156:161-9. 2008
    ..We sought to examine the frequency of mutations in LMNA, the gene encoding lamin A/C, in patients with idiopathic (IDC) or familial dilated cardiomyopathy (FDC)...
  10. ncbi Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes
    M Silberbach
    Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon 97201, USA
    J Biol Chem 274:24858-64. 1999
    ..Thus, ANF expression might function as the natural defense of the heart against maladaptive hypertrophy through its ability to activate ERK...
  11. ncbi The use of positive inotropes in end-of-life heart failure care
    Deirdre J Nauman
    Oregon Health and Science University, Division of Cardiology, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Curr Heart Fail Rep 4:158-63. 2007
    ..The purpose of this review is to provide information about process and implementation of chronic outpatient support with inotropes in patients with end-stage heart failure...
  12. ncbi Morphological analysis of 13 LMNA variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy
    Jason Cowan
    Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Circ Cardiovasc Genet 3:6-14. 2010
    ....
  13. ncbi Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation
    Mark R Vossler
    Oregon Cardiac Transplant Program, Division of Cardiology, Oregon Health Sciences University, Portland 97201, USA
    J Heart Lung Transplant 21:874-81. 2002
    ..CONCLUSION: Pre-operative serum creatinine concentration predicts development of renal insufficiency after heart transplantation...
  14. ncbi Clinical and functional characterization of TNNT2 mutations identified in patients with dilated cardiomyopathy
    Ray E Hershberger
    Division of Cardiovascular Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Circ Cardiovasc Genet 2:306-13. 2009
    ..This is critically important as genetic DCM, usually presenting with advanced, life-threatening disease, may be preventable with early intervention in relatives known to carry the mutation...
  15. ncbi Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy
    Kathy A Crispell
    Department of Medicine/Cardiology, Oregon Health and Science University, Portland, Oregon 97201, USA
    J Am Coll Cardiol 39:1503-7. 2002
    ..CONCLUSIONS: Considerable vigilance for disease presentation and progression is indicated in at-risk members of a kindred with FDC, especially those with incipient FDC...
  16. ncbi Clinical characteristics of 304 kindreds evaluated for familial dilated cardiomyopathy
    Jessica D Kushner
    Division of Cardiology, Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Card Fail 12:422-9. 2006
    ..CONCLUSION: Clinical characteristics of IDC and FDC are similar, precluding an FDC diagnosis from clinical features only...
  17. ncbi Was the decreasing trend in hospital mortality from heart failure attributable to improved hospital care? The Oregon experience, 1991-1995
    H Ni
    Oregon Heart Failure Project, Heart Failure Treatment Program, Division of Cardiology, Oregon Health Sciences University, Portland, USA
    Am J Manag Care 5:1105-15. 1999
    ..To assess the trend in risk-adjusted hospital mortality from heart failure...
  18. ncbi Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure
    Ray E Hershberger
    Department of Medicine/Cardiology, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Card Fail 9:180-7. 2003
    ..The majority of patients died at home and chose to not undergo resuscitation attempts. CONCLUSION: COSI may be an acceptable treatment option for Stage D HF...
  19. ncbi The family history as a tool to identify patients at risk for dilated cardiomyopathy
    Deirdre Nauman
    Department of Medicine, Oregon Health and Science University, Portland, OR, USA
    Prog Cardiovasc Nurs 23:41-4. 2008
  20. ncbi Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy
    Emily L Hanson
    Department of Medicine, Oregon Health Sciences University, Portland, OR 97201, USA
    J Card Fail 8:28-32. 2002
    ..Sudden-onset, rapidly progressive disease was observed in younger individuals. CONCLUSIONS: Cardiac troponin T exon 13 lysine deletions can cause FDC of varying severity and are an important but uncommon cause of FDC...
  21. ncbi Mutations of presenilin genes in dilated cardiomyopathy and heart failure
    Duanxiang Li
    Familial Dilated Cardiomyopathy Research Program, Division of Cardiovascular Medicine and the Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Am J Hum Genet 79:1030-9. 2006
    ..These data indicate that PSEN1 and PSEN2 mutations are associated with DCM and heart failure and implicate novel mechanisms of myocardial disease...
  22. ncbi Becker's muscular dystrophy and orthotopic heart transplantation: perioperative considerations
    Christopher B Komanapalli
    Department of Surgery, Division of Cardiothoracic Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Heart Surg Forum 9:E604-6. 2006
    ..We reviewed our recent experience with Becker's muscular dystrophy patients and discuss the management of perioperative issues specific to this patient group...
  23. ncbi Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy
    Michael Jerosch-Herold
    Division of Cardiology, Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Am J Physiol Heart Circ Physiol 295:H1234-H1242. 2008
    ..56; P = 0.019). The expansion of the extracellular space correlated with reduced MBF and ventricular dilation. Expansion of the extracellular matrix may be a key contributor to contractile dysfunction in IDC patients...
  24. ncbi Clinical and genetic issues in familial dilated cardiomyopathy
    Emily L Burkett
    Division of Cardiology, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OT 97239, USA
    J Am Coll Cardiol 45:969-81. 2005
    ..Genetic testing is not yet commonly available, but its emergence will provide new opportunities for presymptomatic diagnosis...
  25. ncbi Family history: an essential tool for cardiovascular genetic medicine
    Ana Morales
    Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Congest Heart Fail 14:37-45. 2008
    ..Please also give us your feedback, especially to improve the clarity, diversity, and timeliness of the genetic concepts presented. So, away we go...
  26. ncbi Consensus statement: Palliative and supportive care in advanced heart failure
    Sarah J Goodlin
    Institute for Health Care Delivery and Research, Intermountain Health Care, Salt Lake City, Utah 84111, USA
    J Card Fail 10:200-9. 2004
    ....